Why Pfizer Stock Hit A New 52-Week Low Today
Portfolio Pulse from Erica Kollmann
Pfizer, Inc. (NYSE:PFE) shares hit a new 52-week low, falling more than 24% over the last year. The company faces challenges including issues with the commercial roll-out of updated COVID-19 vaccines and uncertainty regarding the approval of its oral antiviral COVID-19 treatment, Paxlovid, for commercial sale in the U.S. market.
September 27, 2023 | 5:22 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Pfizer's stock hit a new 52-week low due to challenges with its COVID-19 vaccine roll-out and uncertainty over the approval of Paxlovid for commercial sale.
Pfizer's stock price is directly impacted by the news. The issues with the vaccine roll-out and the uncertainty over Paxlovid's approval are significant factors affecting the company's performance and investor sentiment, leading to a decrease in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100